A Phase 3 Randomized Double-Blind Trial of Maintenance With Niraparib
Research payments
$881,762
Through program year 2022, $881,762 in research payments was reported against A Phase 3 Randomized Double-Blind Trial of Maintenance With Niraparib, across 99 payments, paid by GlaxoSmithKline, LLC..
- Paid by
- GlaxoSmithKline, LLC.
- ClinicalTrials.gov
- No trial number was reported for this study
By program year
4 rows| Year | Kind | Amount | Payments |
|---|---|---|---|
| 2022 | Research | $304,031 | 15 |
| 2021 | Research | $5,934 | 4 |
| 2020 | Research | $525,381 | 76 |
| 2019 | Research | $46,415 | 4 |
Breakdown
Usually the institution or organisation running the study, not a person.
Records
Every payment, record by record
Date, amount, who was paid and what for — filter by year and kind, or download as CSV, free, in files of 5,000 rows.
Principal investigators named
8 shownNamed on the study's payments. Being named is not being paid: the money in the figures above went to the recipients listed, not necessarily to these people.
- Jonathan Berek Stanford, CA Named on 15 payments
- Howard Burris Nashville, TN Named on 14 payments
- Veena John Staten Island, NY Named on 11 payments
- Kathleen Moore Oklahoma City, OK Named on 9 payments
- Corrine Zarwan Burlington, MA Named on 5 payments
- Masoud Azodi New Haven, CT Named on 5 payments
- Robert Wenham Tampa, FL Named on 4 payments
- Noelle Cloven Fort Worth, TX Named on 3 payments
What you are looking at
Research payments are tied to a study. Being named on a study as a principal investigator is reported separately from being paid as a recipient, and the two are not the same thing — a named investigator has not necessarily received the money.